Studies in nearly 500 cases of NSCLC have found that 80% of CD68 macrophages highly expressed PD-L1, these patients had longer overall survival (OS) when treated with anti-PD-1/PD-L1 axis therapy [112]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.